Pasadena R&D Tax Credit for Businesses Explained

R&D Tax Credits for Pasadena, California Businesses

Pasadena, California, is a vibrant city known for its contributions to science, technology, education, and culture. The city is home to renowned institutions such as Caltech (California Institute of Technology), a world-leading research university; Jet Propulsion Laboratory (JPL), a premier center for space exploration; and Huntington Hospital, a top-tier healthcare provider. Additionally, Pasadena hosts innovative companies in biotechnology, engineering, and creative industries. The Research and Development (R&D) Tax Credit can support these industries by reducing their tax liabilities, encouraging innovation, and improving business performance.

find out more

Are you eligible?

Why choose us?

Pass an Audit?

Swanson Reed is one of the only companies in the United States to exclusively focus on R&D tax credit preparation. Swanson Reed’s office location at 115 W California Boulevard, Pasadena provides R&D tax credit consulting and advisory services to Pasadena and the surrounding areas such as: Los Angeles, Long Beach, Glendale, Santa Clarita and Burbank.

If you have any questions or need further assistance, please call or email our local Pasadena Partner on (323) 287-5311.
Feel free to book a quick teleconference with one of our California R&D tax credit specialists at a time that is convenient for you. Click here for more information about R&D tax credit management and implementation.

Schedule a Teleconference

Pasadena, California Patent of the Year – 2024/2025

Lixte Biotechnology Inc. has been awarded the 2024/2025 Patent of the Year for its groundbreaking cancer-targeted prodrug innovation. Their invention, detailed in U.S. Patent No. 11866444, titled ‘Oxabicycloheptane prodrugs’, utilizes a novel oxabicycloheptane-based compound to deliver endothall directly to cancer cells.

This patented method enables precise in vivo delivery of endothall, a potent anti-cancer agent, to malignant cells while minimizing exposure to healthy tissue. The technology holds particular promise for treating aggressive brain cancers such as glioblastoma multiforme and medulloblastoma. By improving drug targeting, it aims to enhance treatment efficacy and reduce side effects.

The innovation builds upon Lixte’s lead compound, LB-100, a first-in-class PP2A inhibitor currently under clinical investigation. LB-100 is being tested in combination with immunotherapies at leading institutions, including MD Anderson Cancer Center and the Netherlands Cancer Institute. These trials explore its potential to boost immune response and improve outcomes in ovarian and colorectal cancers .

Lixte’s expanding patent portfolio underscores its commitment to advancing targeted cancer therapies. The company’s focus on precision delivery systems reflects a broader trend in oncology toward personalized, less toxic treatments. As clinical trials progress, this latest patent positions Lixte at the forefront of next-generation cancer drug development.